ALKS 8700

Drug Profile

ALKS 8700

Alternative Names: ALKS-8700

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Alkermes plc
  • Class Fumarates; Small molecules
  • Mechanism of Action Immunomodulators; NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Multiple sclerosis

Most Recent Events

  • 16 Mar 2017 Alkermes initiates enrolment in the EVOLVE-2 phase III trial for Multiple Sclerosis in USA
  • 17 Feb 2017 Alkermes has patent protection for ALKS 8700 in USA (Alkermes plc 10-K, February 2017)
  • 16 Dec 2015 Alkermes plans a phase III trial for Multiple sclerosis in USA (Alkermes plc 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top